Ginkgolide B

Ginkgolide B is a member of the ginkgolides, a family of structurally intricate diterpenoid trilactones isolated from Ginkgo biloba. Along with the closely related compound bilobalide, the ginkgolides make up the terpene trilactone fraction that is considered among the most characteristic components of standardized ginkgo leaf extracts ^[1]. Each ginkgolide shares a caged skeleton of six five-membered rings, including three lactone groups and a spirononane framework, and bears an unusual tert-butyl substituent rarely seen in natural products. Ginkgolide B differs from the other ginkgolides in the number and position of its hydroxyl groups and is generally present at low concentrations, typically well below one percent of the extract.

The ginkgolides were first isolated in the 1930s, and their structures were determined in the 1960s ^[1]. Their architectural complexity made them prominent targets for total synthesis, and elegant laboratory syntheses were eventually completed, although the natural material continues to be obtained mainly by extraction from ginkgo trees. Because the terpene trilactones are thought to contribute to the neuromodulatory effects ascribed to ginkgo, they have been widely investigated as pharmacological tools ^[1].

Ginkgolide B is studied chiefly for its antagonism of platelet-activating factor (PAF), a phospholipid signaling molecule that promotes platelet aggregation, inflammation, and nociception. Experimental work has shown that it can blunt PAF-driven responses in immune cells and protect tissues from PAF-mediated injury; for example, it reduced markers of acute liver damage in an animal model of drug toxicity ^[3], and it inhibited the adhesion, chemotaxis, and degranulation of neutrophils stimulated by PAF ^[4]. As a naturally occurring PAF receptor antagonist, it is frequently cited among the most representative herbal agents of its class ^[2]. Small clinical explorations have examined ginkgolide B for migraine prevention, with an open-label study in young patients reporting reduced attack frequency, though such trials are preliminary ^[5].

Ginkgolide B is not an approved medicine in most jurisdictions and is encountered mainly as a research chemical or as a constituent of standardized ginkgo leaf extracts rather than as an isolated consumer product. In some countries a related injectable ginkgo diterpene lactone preparation is used clinically for cerebrovascular indications. As an isolated compound it is used primarily in laboratory pharmacology, where it also serves as a probe of glycine and other ligand-gated ion channel receptors.

Within standardized ginkgo extracts it has a long record of reasonable tolerability. The main caution is bleeding risk, since PAF antagonism and anti-platelet effects can add to blood thinners and should be considered before surgery. GI upset and headache are possible.